Collin is a Scientist at EpigenDx in product and business development. He graduated from the Pennsylvania State University in 2023 with his Ph.D. in Plant Biology with a focus in genetics, specifically in the accumulation and biogenesis of microRNAs and secondary small interfering RNAs.
Christopher Garris is an Assistant professor at the Massachusetts General Hospital. By monitoring key hallmarks of anti-tumor immune function, we have developed novel platforms for combination immunotherapy selection in the re-programming of myeloid cells towards anti-tumor phenotypes.
Dr. Borriello is Harvard Trained Pathologist having trained at the Brigham and Women’s Hospital in the division of immunology where he worked with Arlene Sharpe and Gordon Freeman on the B7-CD28 pathway; co-authoring several pivotal papers in the costimulatory field. He obtained his MD, PhD degrees at the Albert Einstein College of Medicine in NYC where he also worked with Dr. Stanley Nathenson on structure-function relationships in the MHC Class I surface antigens. Dr. Borriello transitioned from academic life to the pharmaceutical/financial sectors in 1999 and has been a pharma business development professional since 2006. In 2016, he was the head of search and evaluation at Baxalta across multiple therapeutic areas until the Shire acquisition, after which he left to found Alloplex Biotherapeutics in pursuit of an idea of his own invention in tumor immunology. He currently lives with his wife and daughter in the Boston area.
Rakesh Dixit is a President & CEO, BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. Accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, AstraZeneca.
